Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region

被引:46
作者
de Jong, BA
Huizinga, TWJ
Zanelli, E
Giphart, MJ
Bollen, ELEM
Uitdehaag, BMJ
Polman, CH
Westendorp, RGJ
机构
[1] Leiden Univ, Ctr Med, Dept Internal Med, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Ctr Med, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Ctr Med, Dept Rheumatol, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Ctr Med, Dept Immunohaematol & Blood Transfus, NL-2300 RC Leiden, Netherlands
[5] Leiden Univ, Ctr Med, Dept Neurol, NL-2300 RC Leiden, Netherlands
[6] Free Univ Amsterdam, Ctr Med, Dept Neurol, Amsterdam, Netherlands
关键词
D O I
10.1212/WNL.59.4.549
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Human leukocyte antigen (HLA)-DR2 carriership is associated with an increased risk for MS. Genome searches using microsatellite markers have consistently shown that additional genetic factors contribute to susceptibility for MS. Objective: To identify loci within the HLA region that predispose to relapse-onset MS independently of HLA-DR2. Method: A case-control study involving 159 patients with definite relapse-onset MS and 273 control subjects was conducted. Six highly polymorphic microsatellite markers encoded within the HLA-C to DR region, that is, D6S1014, D6S273, TNFa, MIB, C1_2_5, and C1_3_2, three single-nucleotide tumor necrosis factor (TNF) promoter gene polymorphisms at positions -238, -308, and -376, and HLA-DR2 carriership were typed. Results: These data confirmed the well-known association between the HLA-DR2 haplotype and relapse-onset MS, yielding an odds ratio (OR) of 3.6 (95% CI: 2.4 to 5.4; p < 0.0001). Multivariate analyses revealed that C1_3_2*354 was also associated with an increased risk for developing relapse-onset MS independently of HLA-DR2 (OR: 2.0; 95% CI: 1.2 to 3.1; p = 0.004). This allele is encoded within an ancestral haplotype that is highly linked to HLA-DR3. The joint effect of this ancestral haplotype and HLA-DR2 resulted in an OR of 8.7 (95% CI: 2.7 to 29; p < 0.0001) to develop relapse-onset MS. In addition, a protective risk factor was found: carriers of TNFa*107 had a 0.5-fold lower risk to develop relapse-onset MS (95% CI: 0.3 to 0.9; p = 0.026). Conclusion: Within the HLA region, other loci besides HLA-DR2 haplotype modulate susceptibility for relapse-onset MS.
引用
收藏
页码:549 / 555
页数:7
相关论文
共 39 条
[1]   MICROSATELLITE, RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM, AND SEQUENCE-SPECIFIC OLIGONUCLEOTIDE TYPING OF THE TUMOR-NECROSIS-FACTOR REGION - COMPARISONS OF THE 4AOHW CELL PANEL [J].
ABRAHAM, LJ ;
MARLEY, JV ;
NEDOSPASOV, SA ;
CAMBONTHOMSEN, A ;
CROUAUROY, B ;
DAWKINS, RL ;
GIPHART, MJ .
HUMAN IMMUNOLOGY, 1993, 38 (01) :17-23
[2]   Complete sequence and gene map of a human major histocompatibility complex [J].
Beck, S ;
Geraghty, D ;
Inoko, H ;
Rowen, L ;
Aguado, B ;
Bahram, S ;
Campbell, RD ;
Forbes, SA ;
Guillaudeux, T ;
Hood, L ;
Horton, R ;
Janer, M ;
Jasoni, C ;
Madan, A ;
Milne, S ;
Neville, M ;
Oka, A ;
Qin, S ;
Ribas-Despuig, G ;
Rogers, J ;
Shiina, T ;
Spies, T ;
Tamiya, G ;
Tashiro, H ;
Trowsdale, J ;
Vu, Q ;
Williams, L ;
Yamazaki, M .
NATURE, 1999, 401 (6756) :921-923
[3]  
BEGOVICH AB, 1992, J IMMUNOL, V148, P249
[4]  
Bitti PP, 2001, GENET EPIDEMIOL, V20, P271, DOI 10.1002/1098-2272(200102)20:2<271::AID-GEPI9>3.0.CO
[5]  
2-L
[6]   Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in Multiple Sclerosis and it's influence on the regulation of TNF-alpha production [J].
Braun, N ;
Michel, U ;
Ernst, BP ;
Metzner, R ;
Bitsch, A ;
Weber, F ;
Rieckmann, P .
NEUROSCIENCE LETTERS, 1996, 215 (02) :75-78
[7]   TUMOR-NECROSIS-FACTOR MICROSATELLITES IN 4 EUROPEAN POPULATIONS [J].
CROUAUROY, B ;
BRIANT, L ;
BOUISSOU, C ;
STAVROPOULOS, C ;
POCIOT, F ;
CAMBONTHOMSEN, A ;
CLAYTON, J .
HUMAN IMMUNOLOGY, 1993, 38 (03) :213-216
[8]   Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis [J].
Das, P ;
Drescher, KM ;
Geluk, A ;
Bradley, DS ;
Rodriguez, M ;
David, CS .
HUMAN IMMUNOLOGY, 2000, 61 (03) :279-289
[9]  
de Jong BA, 2000, ANN NEUROL, V48, P641, DOI 10.1002/1531-8249(200010)48:4<641::AID-ANA11>3.0.CO
[10]  
2-Z